(LFVN) Lifevantage - Ratings and Ratios
Supplements, Skincare, Probiotics
LFVN EPS (Earnings per Share)
LFVN Revenue
Description: LFVN Lifevantage
Lifevantage Corporation (NASDAQ:LFVN) is a US-based company operating in the Personal Care Products sub-industry, with a market capitalization of $173.21 million. The companys stock is characterized by a relatively low beta of 0.481, indicating lower volatility compared to the overall market.
The Personal Care Products industry is driven by consumer demand for health and wellness products, with key economic drivers including demographic trends, consumer spending habits, and advancements in product formulation. To assess LFVNs performance, key performance indicators (KPIs) such as revenue growth, gross margin, and return on equity (ROE) are crucial. With a reported ROE of 31.13%, LFVN demonstrates a strong ability to generate profits from shareholder equity.
The companys price-to-earnings (P/E) ratio of 19.66 suggests that investors are willing to pay a premium for LFVNs earnings, potentially due to expectations of future growth. However, the forward P/E ratio is not available, indicating a lack of analyst coverage or estimates for future earnings. To further evaluate LFVNs investment potential, it is essential to analyze its revenue streams, product offerings, and competitive positioning within the personal care products market.
From a trading perspective, LFVNs stock price has fluctuated significantly over the past 52 weeks, with a high of $25.47 and a low of $7.61. The current price of $13.49 is below the 52-week high, potentially indicating a buying opportunity. However, a thorough analysis of the companys fundamental drivers and technical indicators is necessary to make an informed investment decision.
LFVN Stock Overview
| Market Cap in USD | 163m |
| Sub-Industry | Personal Care Products |
| IPO / Inception | 2004-10-05 |
LFVN Stock Ratings
| Growth Rating | 15.6% |
| Fundamental | 77.0% |
| Dividend Rating | 56.1% |
| Return 12m vs S&P 500 | 46.0% |
| Analyst Rating | 5.0 of 5 |
LFVN Dividends
| Dividend Yield 12m | 1.25% |
| Yield on Cost 5y | 1.25% |
| Annual Growth 5y | 19.87% |
| Payout Consistency | 100.0% |
| Payout Ratio | 26.2% |
LFVN Growth Ratios
| Growth Correlation 3m | 47.7% |
| Growth Correlation 12m | 4.8% |
| Growth Correlation 5y | 30% |
| CAGR 5y | -0.20% |
| CAGR/Max DD 5y | 0.00 |
| Sharpe Ratio 12m | 0.88 |
| Alpha | 51.37 |
| Beta | -0.389 |
| Volatility | 57.24% |
| Current Volume | 139.3k |
| Average Volume 20d | 80.9k |
| Stop Loss | 12.1 (-7.6%) |
| Signal | -0.81 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (9.15m TTM) > 0 and > 6% of Revenue (6% = 13.3m TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA -2.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.68% (prev 7.46%; Δ 2.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 13.4m > Net Income 9.15m (YES >=105%, WARN >=100%) |
| Net Debt (-10.1m) to EBITDA (16.2m) ratio: -0.62 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.3m) change vs 12m ago 2.42% (target <= -2.0% for YES) |
| Gross Margin 80.29% (prev 79.32%; Δ 0.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 321.0% (prev 335.1%; Δ -14.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -3.83
| (A) 0.28 = (Total Current Assets 54.1m - Total Current Liabilities 32.6m) / Total Assets 77.2m |
| (B) -1.34 = Retained Earnings (Balance) -103.5m / Total Assets 77.2m |
| warn (B) unusual magnitude: -1.34 — check mapping/units |
| (C) 0.19 = EBIT TTM 13.0m / Avg Total Assets 69.3m |
| (D) -2.43 = Book Value of Equity -105.1m / Total Liabilities 43.2m |
| Total Rating: -3.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.97
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 7.83% = 3.92 |
| 3. FCF Margin 5.39% = 1.35 |
| 4. Debt/Equity 0.37 = 2.43 |
| 5. Debt/Ebitda 0.78 = 2.05 |
| 6. ROIC - WACC 25.49% = 12.50 |
| 7. RoE 31.13% = 2.50 |
| 8. Rev. Trend 28.93% = 1.45 |
| 9. Rev. CAGR 5.12% = 0.64 |
| 10. EPS Trend 45.63% = 1.14 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of LFVN shares?
Over the past week, the price has changed by +0.15%, over one month by +1.47%, over three months by +3.52% and over the past year by +70.76%.
Is Lifevantage a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LFVN is around 12.47 USD . This means that LFVN is currently overvalued and has a potential downside of -4.81%.
Is LFVN a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LFVN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18 | 37.4% |
| Analysts Target Price | 18 | 37.4% |
| ValueRay Target Price | 13.4 | 2.1% |
Last update: 2025-08-28 02:51
LFVN Fundamental Data Overview
CCE Cash And Equivalents = 22.5m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 18.4714
P/S = 0.732
P/B = 4.7857
Beta = 0.481
Revenue TTM = 222.3m USD
EBIT TTM = 13.0m USD
EBITDA TTM = 16.2m USD
Long Term Debt = 10.6m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.93m USD (from shortTermDebt, last quarter)
Debt = 12.6m USD (Calculated: Short Term 1.93m + Long Term 10.6m)
Net Debt = -10.1m USD (from netDebt column, last quarter)
Enterprise Value = 152.9m USD (162.8m + Debt 12.6m - CCE 22.5m)
Interest Coverage Ratio = unknown (Ebit TTM 13.0m / Interest Expense TTM 0.0)
FCF Yield = 7.83% (FCF TTM 12.0m / Enterprise Value 152.9m)
FCF Margin = 5.39% (FCF TTM 12.0m / Revenue TTM 222.3m)
Net Margin = 4.12% (Net Income TTM 9.15m / Revenue TTM 222.3m)
Gross Margin = 80.29% ((Revenue TTM 222.3m - Cost of Revenue TTM 43.8m) / Revenue TTM)
Tobins Q-Ratio = -1.46 (set to none) (Enterprise Value 152.9m / Book Value Of Equity -105.1m)
Interest Expense / Debt = 0.85% (Interest Expense 107.0k / Debt 12.6m)
Taxrate = 32.48% (from yearly Income Tax Expense: 1.41m / 4.35m)
NOPAT = 8.76m (EBIT 13.0m * (1 - 32.48%))
Current Ratio = 1.66 (Total Current Assets 54.1m / Total Current Liabilities 32.6m)
Debt / Equity = 0.37 (Debt 12.6m / last Quarter total Stockholder Equity 34.0m)
Debt / EBITDA = 0.78 (Net Debt -10.1m / EBITDA 16.2m)
Debt / FCF = 1.05 (Debt 12.6m / FCF TTM 12.0m)
Total Stockholder Equity = 29.4m (last 4 quarters mean)
RoA = 11.85% (Net Income 9.15m, Total Assets 77.2m )
RoE = 31.13% (Net Income TTM 9.15m / Total Stockholder Equity 29.4m)
RoCE = 32.39% (Ebit 13.0m / (Equity 29.4m + L.T.Debt 10.6m))
RoIC = 29.79% (NOPAT 8.76m / Invested Capital 29.4m)
WACC = 4.29% (E(162.8m)/V(175.3m) * Re(4.58%)) + (D(12.6m)/V(175.3m) * Rd(0.85%) * (1-Tc(0.32)))
Shares Correlation 5-Years: 40.0 | Cagr: 0.03%
Discount Rate = 4.58% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 76.09% ; FCFE base≈11.5m ; Y1≈10.1m ; Y5≈8.09m
Fair Price DCF = 11.69 (DCF Value 147.2m / Shares Outstanding 12.6m; 5y FCF grow -15.80% → 3.0% )
Revenue Correlation: 28.93 | Revenue CAGR: 5.12%
Rev Growth-of-Growth: 10.29
EPS Correlation: 45.63 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -32.32
Additional Sources for LFVN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle